A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2011
05/19/2011	US20110117115 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
05/19/2011	US20110117112 Sodium channel protein type iii alpha-subunit splice variant
05/19/2011	US20110117111 Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
05/19/2011	US20110117108 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
05/19/2011	US20110117107 Compositions and methods for diagnosis, prognosis and management of malaria
05/19/2011	US20110117106 Uses of calpain inhibitors to inhibit inflammation
05/19/2011	US20110117102 Therapeutic uses of inhibitors of RTP801
05/19/2011	US20110117099 Inhibiting staphylococcus epidermidis infections
05/19/2011	US20110117094 Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury
05/19/2011	US20110117092 Compositions and methods for inhibiting g-csfr
05/19/2011	US20110117090 Adam-15 antibodies and immunogenic peptides
05/19/2011	US20110117084 Vandetanib derivatives
05/19/2011	US20110117081 Functionalized pyrrolidines and use thereof as iap inhibitors
05/19/2011	US20110117078 Methods for the Treatment of Cancers
05/19/2011	US20110117073 Protein Kinase Conjugates and Inhibitors
05/19/2011	US20110117070 Compositions and methods for treating headache
05/19/2011	US20110117057 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
05/19/2011	US20110117055 Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
05/19/2011	US20110117054 Use of ribavirin in blood coagulation disorder
05/19/2011	US20110117053 Method of modulating fibroblast accumulation or collagen deposition
05/19/2011	US20110117051 Method for inducing and accelerating cells
05/19/2011	US20110117050 Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen
05/19/2011	US20110117049 Methods and Compositions for Modulating Adipocyte Function
05/19/2011	US20110117048 Method and composition for use in preparation of a patient for surgery
05/19/2011	US20110117047 Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
05/19/2011	US20110117038 Dopa Oxidase Inhibitor, Skin-Lightening Agent and External Preparation for Skin
05/19/2011	US20110117036 Compositions and Methods for Improving Skin Appearance
05/19/2011	US20110117032 Santising compositions and methods
05/19/2011	US20110117030 Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections
05/19/2011	US20110117029 Water-soluble anionic bacteriochlorophyll derivatives and their uses
05/19/2011	US20110117026 Methods and compositions for the delivery of bioactive compounds
05/19/2011	US20110117022 Method of using and establishing an absorption rate level and a neuron firing level
05/19/2011	US20110117019 Novel Compositions and Uses Thereof
05/19/2011	US20110117015 Diagnostic Agents Selective Against Metalloproteases
05/19/2011	US20110117009 Drug conjugates with polyglycerols
05/19/2011	US20110117008 Use of avicins to deliver therapeutic and diagnostic agents
05/19/2011	DE202010016235U1 Formulierungen Formulations
05/19/2011	DE112008000888T5 Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen Non-specific delayed hypersensitivity response for the treatment of herpes simplex virus infections
05/19/2011	DE102010048788A1 Transdermal system, useful e.g. as monotherapy for indicating e.g. multiple sclerosis, comprises immunomodulator as active agent and active agent-impermeable removable protective coating, adhesive layer and active agent permeable membrane
05/19/2011	DE102009053562A1 Pharmaceutical composition, useful for treating diabetes mellitus type 2 in a combination therapy with other antidiabetic agent, comprises rosiglitazone succinate as an active agent
05/19/2011	CA2817198A1 Compositions and methods for treating hyperproliferative disorders
05/19/2011	CA2812929A1 Compositions and methods for treating hyperproliferative disorders
05/19/2011	CA2796161A1 Spiropiperidine compounds as orl-1 receptor antagonists
05/19/2011	CA2789879A1 Dimeric smac mimetics
05/19/2011	CA2781056A1 Kinase inhibitors
05/19/2011	CA2781054A1 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
05/19/2011	CA2781041A1 Spiropiperidine compounds as orl-1 receptor antagonists
05/19/2011	CA2780941A1 Immediate release tablet formulations
05/19/2011	CA2780940A1 Crystalline forms of neurotrophin mimetic compounds and their salts
05/19/2011	CA2780938A1 Reduced mass metformin formulations
05/19/2011	CA2780892A1 Kinase inhibitors
05/19/2011	CA2780860A1 Pharmaceutical composition for external use
05/19/2011	CA2780835A1 Par-1 antagonists for use in the treatment or prevention of influenza virus type a infections
05/19/2011	CA2780812A1 Hepatitis c virus inhibitors
05/19/2011	CA2780772A1 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
05/19/2011	CA2780732A1 Androgen receptor modulator and uses thereof
05/19/2011	CA2780723A1 Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
05/19/2011	CA2780704A1 Drug combination with theobromine and its use in therapy
05/19/2011	CA2780703A1 Drug combination with theobromine and its use in therapy
05/19/2011	CA2780683A1 Therapeutic or prophylactic agent for diabetes
05/19/2011	CA2780641A1 Selective heterocyclic sphingosine 1 phosphate receptor modulators
05/19/2011	CA2780633A1 Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
05/19/2011	CA2780627A1 Novel mannopyranoside derivatives with anticancer activity
05/19/2011	CA2780614A1 Treatment of microbial infections
05/19/2011	CA2780611A1 Pharmaceutical combination of prostaglandin compound and nsaid for the treatment of glaucoma and ocular hypertension
05/19/2011	CA2780568A1 Oxazoline derivatives for treatment of cns disorders
05/19/2011	CA2780563A1 Antisense molecules and methods for treating pathologies
05/19/2011	CA2780547A1 Spiro-oxindole mdm2 antagonists
05/19/2011	CA2780495A1 Tivozanib and temsirolimus in combination
05/19/2011	CA2780486A1 Stabilized formulations of fatty acids
05/19/2011	CA2780433A1 Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
05/19/2011	CA2780382A1 Pemirolast for the treatment of systemic low grade inflammation
05/19/2011	CA2780365A1 Mammalian metabolites of steroids
05/19/2011	CA2780292A1 Nanosus pens ion of a poorly soluble drug made by microfluidization process
05/19/2011	CA2780282A1 Homoglutamic acid derivatives
05/19/2011	CA2780256A1 Use of bethanechol for treatment of xerostomia
05/19/2011	CA2780234A1 Polysaccharide gel formulation having multi-stage bioactive agent delivery
05/19/2011	CA2780160A1 Methods and compositions for rapid treatment of otitis externa
05/19/2011	CA2780031A1 A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
05/19/2011	CA2780018A1 N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
05/19/2011	CA2779843A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
05/19/2011	CA2779830A1 Antisense antiviral compound and method for treating influenza viral infection
05/19/2011	CA2779508A1 Method and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
05/19/2011	CA2779303A1 Bicyclic pyridines and analogs as sirtuin modulators
05/19/2011	CA2779088A1 [1,5]-diazocin derivatives
05/19/2011	CA2778886A1 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
05/19/2011	CA2778880A1 Methods of treating or preventing stent thrombosis
05/19/2011	CA2778693A1 Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
05/19/2011	CA2778686A1 N-9-substituted purine compounds, compositions and methods of use
05/19/2011	CA2778316A1 N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
05/19/2011	CA2778229A1 Methods for maintaining eye health and ameliorating ophthalmic maladies in canines
05/19/2011	CA2778175A1 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
05/19/2011	CA2778174A1 Tricyclic pyrazol amine derivatives
05/19/2011	CA2777682A1 Dendrimer compositions and methods of synthesis
05/19/2011	CA2776829A1 Compounds for pim kinase inhibition and for treating malignancy
05/19/2011	CA2776797A1 Pharmaceutical composition
05/18/2011	EP2322929A1 Diagnostics, drug screening and treatment for cancer
05/18/2011	EP2322668A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms.
05/18/2011	EP2322667A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms.
05/18/2011	EP2322666A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms.

1 ... 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 ... 7860